Loading...
Please wait, while we are loading the content...
Similar Documents
Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
| Content Provider | Europe PMC |
|---|---|
| Author | Wu, Shao-Jie Ruan, Dan-Dan Wu, Qiu-Yan Tang, Yi Zhang, Jian-Hui Cai, Sen-Lin Zhou, Yan-Feng Luo, Jie-Wei Fang, Zhu-Ting |
| Copyright Year | 2023 |
| Abstract | BackgroundDrug-eluting bead transarterial chemoembolization (DEB-TACE) has good efficacy in the treatment of unresectable hepatocellular carcinoma (uHCC), with a relatively high objective response rate (ORR) compared to conventional transarterial chemoembolization (cTACE). This study aimed to evaluate the safety and medium-term clinical efficacy of DEB-TACE combined with lenvatinib (LEN) plus PD-1 inhibitors as a triple therapy for the treatment of uHCC.MethodsData of patients with uHCC who received triple therapy of DEB-TACE combined with LEN plus PD-1 inhibitors from January 2019 to June 2021 were analyzed retrospectively. The study endpoints were ORR, progression-free survival (PFS), and treatment-related adverse events based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST).ResultsThirty-five patients were included in this study, with a median follow-up period of 15 months. The median cycle of DEB-TACE was 1, while that of all forms of TACE procedures per patient was 2. The median administration time of LEN was 7 months, and the median number of PD-1 inhibitor treatment was 4 cycles. The ORR based on mRECIST was 82.9%, disease control rate was 91.4%, and the median time to response was 7 weeks. Among these, the ORR of Barcelona Clinic Liver Cancer (BCLC) stage A reached 100%, while that of BCLC stages B and C reached 84.6% and 78.9%, respectively. The median PFS was 9 months; the mOS was not reached. Fourteen patients (40%) successfully underwent downstaging conversion and surgical resection, 32 patients (91.4%) experienced treatment-related adverse events, and no grade 5-related adverse reactions occurred.ConclusionDEB-TACE combined with LEN and PD-1 inhibitors has a high ORR and surgical conversion rate in the treatment of uHCC tumors, and the toxicity and side effects were tolerable. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10244613&blobtype=pdf |
| Page Count | 14 |
| Journal | Journal of Hepatocellular Carcinoma [J Hepatocell Carcinoma] |
| Volume Number | 10 |
| PubMed Central reference number | PMC10244613 |
| PubMed reference number | 37292114 |
| e-ISSN | 22535969 |
| DOI | 10.2147/jhc.s408819 |
| Language | English |
| Publisher | Dove |
| Publisher Date | 2023-06-02 |
| Access Restriction | Open |
| Rights License | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Wu et al. |
| Subject Keyword | unresectable hepatocellular carcinoma transarterial chemoembolization drug-eluting bead lenvatinib PD-1 inhibitor combined therapy |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hepatology Oncology |
